Amgen announced it will present comprehensive new data from its obesity and cardiovascular programs at the 85th American Diabetes Association (ADA) Scientific Sessions, taking place June 20–23, 2025, in Chicago. Highlights include full 52-week results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), as well as new findings from the Phase 3 FOURIER trial of Repatha® (evolocumab) and the real-world VESALIUS-REAL study on lipid management.
MariTide, an investigational long-acting peptide-antibody conjugate administered subcutaneously once a month or less frequently, will be the focus of an expert-led symposium scheduled for Monday, June 23 from 1:30 p.m. to 3:00 p.m. CDT (Location: W375 A). The symposium will feature detailed efficacy, safety, and tolerability data from 52 weeks of Part 1 of the Phase 2 trial, full data from the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study, and updates on the ongoing Phase 3 MARITIME Chronic Weight Management studies. Preliminary topline results from the Phase 2 study were previously released in November 2024.
"We are excited to share these important findings from our cardiometabolic pipeline," said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. "The 52-week data from the MariTide Phase 2 study show robust, sustained weight loss without evidence of plateauing in patients with obesity, both with and without Type 2 diabetes. These results have been instrumental in shaping our Phase 3 MARITIME program, and we believe MariTide has the potential to become a differentiated treatment option for people living with obesity and related metabolic disorders."
In conjunction with the ADA meeting, Amgen will host an investor webcast on Monday, June 23 at 4:30 p.m. CDT. Dr. Bradner and other members of Amgen’s management team will provide updates on the MariTide program. The webcast will be accessible via Amgen’s Investor Relations website and will remain available for replay for at least 90 days.
Amgen will also sponsor the ADA Interactive Obesity Experience, inviting attendees to engage in a word cloud project at Booth #1338 and participate in an immersive video presentation in the ADA Member Lounge.
In addition to the MariTide data, Amgen will present key cardiovascular findings:
FOURIER Trial: Cardiovascular Efficacy of Evolocumab in Persons with Type 1 Diabetes Mellitus (Abstract #1991) — Sunday, June 22, 12:30–1:30 p.m. CDT.
VESALIUS-REAL Study: Lipid-lowering Therapy Patterns in High-Risk Diabetes Patients (Abstract #1315) — Saturday, June 21, 12:30–1:30 p.m. CDT.
On-demand access to ADA sessions will begin June 25, 2025.